Korro Bio (KRRO) 10% Owner LP Buys $30K of Stock
Key Points
- Lynx1 Capital Management now owns 1,599,665 shares of Korro Bio, reflecting a 0.16% increase in its holdings.
- Korro Bio's stock closed at $11.98 on the day of the purchase and recently traded around $12.02, which is above its 50-day and 200-day moving averages.
- Analysts maintain a positive outlook with a consensus recommendation of 'strong buy' and a mean price target of $20.20.
Since the trade, $KRRO is up 0.3% to date (from the $11.98 close on Oct 23, 2026).
Get Korro Bio text alerts
We text you when insiders, Congress, analysts or big funds move on $KRRO.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Korro Bio, Inc. alert may contain errors. Disclosures
Lynx1 Capital Management LP bought 2,510 shares of Korro Bio, Inc. (NASDAQ: KRRO) on October 23, 2026, for about $30,386. The purchase price was $12.11 per share, which is slightly above the stock's closing price of $11.98 on the same day. This transaction increases Lynx1's total holdings in Korro to 1,599,665 shares.
KRRO
Korro Bio, Inc.
Lynx1 Capital Management LP vs. the S&P 500
Hypothetical returns from Lynx1 Capital Management LP's disclosed trades, not real profit or advice. How we model this.
What Changed in Lynx1 Capital Management's Korro Bio Position
Lynx1 Capital Management's stake in Korro Bio grew by 2,510 shares, reflecting a 0.16% increase in their holdings. The investment highlights the firm's continued confidence in the biotechnology company.
Other Institutional Activity in Korro Bio
Several other institutional investors hold significant stakes in Korro Bio. Lynx1 Capital Management LP has 1,538,296 shares valued at about $18.5 million, while NEA Management Company, LLC owns 1,297,893 shares worth around $15.6 million. Venrock Adviser, LLC holds 1,009,500 shares valued at approximately $12.1 million. Atlas Venture Life Science Advisors, LLC trimmed its position by 174,201 shares, now holding 962,884 shares worth about $11.6 million. Balyasny Asset Management LP reduced its stake by 88,303 shares, ending with 951,783 shares valued at about $11.4 million.
Korro Bio, Inc. Stock Down 0.2%
As of October 26, 2026, Korro Bio shares recently traded around $12.02, which is above its 50-day moving average of $11.38 and its 200-day average of $11.82. However, the stock is still 71.9% below its 52-week high of $42.70, indicating significant volatility in its price.
Recent Earnings
Korro Bio reported trailing twelve-month revenue of $2,382,000 with a net margin of 0.0%. The company is set to announce its next earnings on November 12, 2026. It currently has a forward P/E ratio of -2.71, reflecting its ongoing challenges in profitability.
Insider Buying and Selling at Korro Bio, Inc.
Recent insider transactions include sales by Formela Jean Francois, who sold a total of 119,005 shares on June 23, 2026, and 48,438 shares on June 24, 2026. Todd Chappell, the Chief Operating Officer, sold 3,168 shares on June 16, 2026. These sales occurred before Lynx1's recent purchase.
Analysts Set New Price Targets
On October 6, 2026, HC Wainwright & Co. reiterated its 'Buy' rating for Korro Bio with a price target of $15.00. The consensus among analysts is a strong buy with a mean price target of $20.20, based on ten analyst opinions.
About Korro Bio
Korro Bio, Inc. is a biopharmaceutical company focused on developing genetic medicines through RNA editing to treat rare diseases. Its lead product candidate, KRRO-121, targets hyperammonemia, showcasing the company's innovative approach in biotechnology.
Bottom Line
Investors should keep an eye on Korro Bio's upcoming earnings report on November 12, 2026, as it may provide insights into the company's performance and future outlook. Lynx1's recent acquisition adds to the ongoing interest in Korro Bio amid recent insider sales and analyst support.
Related Filing Alerts
Source: Lynx1 Capital Management LP's Form 4 filing on $KRRO (Oct 23, 2026). Written by software, not financial advice. How we make alerts